X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA FRESENIUS KABI ONCO. SUN PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 31.8 22.1 143.8% View Chart
P/BV x 2.7 3.1 85.5% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 SUN PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
FRESENIUS KABI ONCO.
Mar-13
SUN PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs701176 398.0%   
Low Rs43379 551.8%   
Sales per share (Unadj.) Rs110.437.7 293.0%  
Earnings per share (Unadj.) Rs11.05.1 215.5%  
Cash flow per share (Unadj.) Rs17.26.7 256.3%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.842.5 373.3%  
Shares outstanding (eoy) m2,399.26158.23 1,516.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.4 152.1%   
Avg P/E ratio x51.625.0 206.7%  
P/CF ratio (eoy) x32.918.9 173.8%  
Price / Book Value ratio x3.63.0 119.3%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,02120,135 6,754.6%   
No. of employees `00017.81.2 1,544.2%   
Total wages/salary Rs m53,671703 7,632.3%   
Avg. sales/employee Rs Th14,890.95,176.2 287.7%   
Avg. wages/employee Rs Th3,017.1610.4 494.3%   
Avg. net profit/employee Rs Th1,480.6699.6 211.6%   
INCOME DATA
Net Sales Rs m264,8955,963 4,442.3%  
Other income Rs m8,38818 46,597.8%   
Total revenues Rs m273,2825,981 4,569.2%   
Gross profit Rs m56,0811,430 3,921.5%  
Depreciation Rs m14,998258 5,815.6%   
Interest Rs m5,176-26 -19,906.5%   
Profit before tax Rs m44,2951,216 3,642.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,505-68 13,957.4%   
Tax Rs m8,452342 2,469.9%   
Profit after tax Rs m26,338806 3,268.1%  
Gross profit margin %21.224.0 88.3%  
Effective tax rate %19.128.1 67.8%   
Net profit margin %9.913.5 73.6%  
BALANCE SHEET DATA
Current assets Rs m316,3595,102 6,201.2%   
Current liabilities Rs m198,6432,385 8,327.5%   
Net working cap to sales %44.445.6 97.6%  
Current ratio x1.62.1 74.5%  
Inventory Days Days95150 63.2%  
Debtors Days Days108113 95.1%  
Net fixed assets Rs m213,1785,148 4,140.9%   
Share capital Rs m2,399158 1,516.6%   
"Free" reserves Rs m378,6066,556 5,775.3%   
Net worth Rs m381,0066,732 5,659.8%   
Long term debt Rs m17,721952 1,861.0%   
Total assets Rs m643,02810,388 6,190.1%  
Interest coverage x9.6-45.8 -20.9%   
Debt to equity ratio x00.1 32.9%  
Sales to assets ratio x0.40.6 71.8%   
Return on assets %4.97.5 65.3%  
Return on equity %6.912.0 57.7%  
Return on capital %10.014.6 68.6%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m40,8165,298 770.5%   
Fx outflow Rs m30,1431,772 1,700.9%   
Net fx Rs m10,6733,525 302.7%   
CASH FLOW
From Operations Rs m39,0721,274 3,066.6%  
From Investments Rs m-33,708-1,204 2,799.2%  
From Financial Activity Rs m-15,393-196 7,849.4%  
Net Cashflow Rs m-7,359-126 5,826.7%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 5.1 0.3 1,710.0%  
FIIs % 23.0 9.6 239.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 9.1 91.2%  
Shareholders   133,026 42,599 312.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  BIOCON   FULFORD INDIA  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Crude Oil Prices, June Quarter Results, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets extended their decline for the 2nd day as markets witnessed a sharp sell-off amid disappointing earnings and slowing economic growth concerns.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jul 22, 2019 09:17 AM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS